New oral sedative studied in children to improve pre-surgery dosing
NCT ID NCT03639428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how a new oral form of midazolam (ADV6209) is processed in the body of children aged 6 months to 17 years before surgery. 37 children received a single dose based on their weight. Researchers measured drug levels in the blood to understand how age affects clearance and to support future dosing recommendations. The goal was not to test effectiveness but to gather pharmacokinetic data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- midazolam (oral solution ADV6209)
- What this could lead to
- If successful, this could lead to better dosing guidelines for midazolam in children, making pre-surgery sedation safer and more predictable.
- What could go wrong
- This is a small, early-phase study (37 children) focused on drug levels, not on proving effectiveness or safety. Results may not apply to all children or clinical settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIDAZOLAM are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.